Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02197078 · ClinicalTrials.gov registry record

Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin

A clinical trial, sponsored by Boehringer Ingelheim.

Completed
Registry status
189,426
Enrollment target

NCT02197078: Completed study, sponsored by Boehringer Ingelheim.

NCT02197078 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 189,426 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02197078 has completed, sponsored by Boehringer Ingelheim.

COMPLETED
Registry status
189,426 participants
Enrollment target

Study Summary

This protocol is for a series of comparative effectiveness and safety analyses within periodically updated cohorts of patients initiating linagliptin, other DPP-4 inhibitors, and other oral hypoglycemic medications, followed longitudinally for the occurrence of a variety of health outcomes. The primary analysis will be conducted among patients without prior within-class medication use.

Primary Outcome

Number of participants with major adverse cardiovascular event is presented by the number of patients reported a composite of: * Coronary revascularization (elective and non-elective procedure) * Acute coronary syndrome (ACS), including acute myocardial infarction (MI) * Stroke (Ischemic and hemorrhagic stroke)

Trial Details

FieldValue
Enrollment Target 189,426 participants
Start Date 2014-07-30
Est. Completion 2019-02-26
Boehringer Ingelheim

515 total trials

What the finished NCT02197078 record still lists

NCT02197078 is an observational study that tracks outcomes without assigning an intervention. Its 189,426 participants enrollment target places it among the larger protocols in the corpus.

The record links to 0 conditions, and to 0 interventions.

NCT02197078 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02197078 about?

NCT02197078 is a clinical study titled "Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin". This protocol is for a series of comparative effectiveness and safety analyses within periodically updated cohorts of patients initiating linagliptin, other DPP-4 inhibitors, and other oral hypoglycemic medications, followed longitudinally for the occurrence of a variety of health outcomes. The prim...

What is the current status of trial NCT02197078?

This trial is currently completed. The enrollment target is 189,426 participants. The study started on 2014-07-30. Estimated completion is 2019-02-26.

Who is sponsoring clinical trial NCT02197078?

This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06090578 · 180,000 participants · NA

    TabCAT Brain Health Assessment in Primary Care

  • NCT06917339 · 156,000 participants

    Retrospective Analyses of TrakStar Database

  • NCT06232551 · 152,000 participants · NA

    Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism

  • NCT05994482 · 130,000 participants

    Surveillance Colonoscopy in Older Adults: The SurvOlderAdults Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02197078, the US trial registry maintained by the National Library of Medicine. NCT02197078 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.